AndhraNews.net
Home » Business News » 2011 » October » October 27, 2011

Implant Sciences Explosives Detection Technology Protects Major European Bank


October 27, 2011 - Wilmington, MA

Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced sales of its Quantum Sniffer™ QS-H150 portable explosives trace detection devices to two new customers in Europe. Units have been sold for deployment in the protection of a major European bank and for use in training at an international explosives ordinance disposal (EOD) school.

"The current economic and political environment in much of the world, Europe included, makes the protection of financial institutions a necessity. The QS-H150 is well suited for use in building security for both private industry and public infrastructures. It has already been deployed in places such as stock exchanges, hotels, and federal facilities. It is a testament to the quality of both our product and our distributors that such a wide range of customers can appreciate the value of our explosives trace detectors," stated Glenn D. Bolduc, President and CEO of Implant Sciences.

About the Quantum Sniffer™ QS-H150
The QS-H150 Quantum Sniffer is a hand-held explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220
The QS-B220 Quantum Sniffer, introduced in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

MarketWire

Comment on this story

Share